Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 691 to 700 of 1334 total matches.

Nebivolol (Bystolic) for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Mar 10, 2008  (Issue 1281)
and renin activity. At higher doses, it antagonizes beta 2 receptors and could cause bronchospasm ...
Nebivolol (Bystolic - Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart failure.
Med Lett Drugs Ther. 2008 Mar 10;50(1281):17-9 |  Show IntroductionHide Introduction

Drugs for Head Lice

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024  (Issue 1704)
Killing Shampoo, and others) to enhance their activity. Pyrethrin formulations are unstable in heat ...
Pediculosis capitis (head lice infestations) occur in all age groups, but especially in elementary school children. In most cases, transmission occurs by head-to-head contact. Pharmacologic treatment is recommended for persons with live lice or eggs (nits) within 1 cm of the scalp. Topical pediculicides should be tried first. Oral therapy is occasionally required for refractory infestations.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):89-92   doi:10.58347/tml.2024.1704a |  Show IntroductionHide Introduction

Gamma Hydroxy Butyrate Poisoning

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 1991  (Issue 836)
, vomiting, dizziness, confusion, and drowsiness to depressed respiration and seizure-like activity. Some ...
Gamma hydroxy butyrate (GHB) sold in health food stores has recently caused outbreaks of gastrointestinal illness, central-nervous-system (CNS) depression, and seizures.
Med Lett Drugs Ther. 1991 Jan 25;33(836):8 |  Show IntroductionHide Introduction

Eribulin Mesylate (Halaven) for Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Apr 18, 2011  (Issue 1362)
is an analog of halichondrin B, a macrolide found in marine sponges that has marked anticancer activity ...
Eribulin mesylate (Halaven – Eisai) has been approved by the FDA for treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapy regimens for metastatic cancer. Prior therapy should have included an anthracycline and a taxane in either an adjuvant or metastatic setting. Other drugs used to treat anthracycline- and taxane-refractory metastatic breast cancer include capecitabine (Xeloda), gemcitabine (Gemzar, and others) and vinorelbine (Navelbine, and others).
Med Lett Drugs Ther. 2011 Apr 18;53(1362):30-1 |  Show IntroductionHide Introduction

Sitagliptin and Simvastatin (Juvisync)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2011  (Issue 1377)
inhibitor simvastatin (Zocor, and others). ACTIVITY — Statins have been shown to lower the risk ...
The FDA has approved Juvisync (Merck), a fixed-dose combination of the antihyperglycemic DPP-4 inhibitor sitagliptin (Januvia) and the HMG-CoA reductase inhibitor simvastatin (Zocor, and others).
Med Lett Drugs Ther. 2011 Nov 14;53(1377):89 |  Show IntroductionHide Introduction

In Brief: New Indications for Secukinumab (Cosentyx)

   
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016  (Issue 1496)
who continue to have active psoriatic arthritis. The cost for one 150 mg/mL single-use pen ...
The FDA has approved the subcutaneous IL-17A antagonist secukinumab (Cosentyx - Novartis), which was first approved in 2015 for treatment of plaque psoriasis, for treatment of psoriatic arthritis and ankylosing spondylitis in adults.1 Secukinumab is one of the most effective drugs available for treatment of plaque psoriasis.2FDA approval of secukinumab for treatment of psoriatic arthritis was based on two randomized, double-blind trials with a primary endpoint of at least a 20% improvement in the American College of Rheumatology response criteria (ACR20) at 24 weeks. In both trials, ACR20...
Med Lett Drugs Ther. 2016 Jun 6;58(1496):76 |  Show IntroductionHide Introduction

Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018  (Issue 1556)
for adequate antiviral activity. 7. Clinical trial data are lacking. 8. Antiviral treatment is recommended ...
The recommendations for treatment of varicella-zoster virus (VZV) and herpes simplex virus (HSV) infections are listed in tables 1 and 2. Vaccination against VZV was reviewed in a previous issue.
Med Lett Drugs Ther. 2018 Sep 24;60(1556):153-7 |  Show IntroductionHide Introduction

Antimicrobial Prophylaxis for Surgery

   
The Medical Letter on Drugs and Therapeutics • May 23, 2016  (Issue 1495)
(Ancef, and others), a first-generation cephalosporin active against many staphylococci and streptococci ...
Antimicrobial prophylaxis can decrease the incidence of postoperative surgical site infection after some procedures. Since the last Medical Letter article on this subject, consensus guidelines have been published. Recommendations for prophylaxis in specific surgical procedures are listed in Table 1.
Med Lett Drugs Ther. 2016 May 23;58(1495):63-8 |  Show IntroductionHide Introduction

Drugs for Thyroid Disorders

   
Treatment Guidelines from The Medical Letter • Aug 01, 2009  (Issue 84)
, as needed, of biologically inactive T4 into biologically active triiodothyronine (T3). In a study of 50 ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 |  Show IntroductionHide Introduction

Isosorbide Mononitrate for Angina

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 1992  (Issue 873)
for prophylactic use in patients with chronic stable angina. ISMN is the major active metabolite of isosorbide ...
Isosorbide mononitrate (ISMN; Ismo - Wyeth-Ayerst), an oral nitrate long available in Europe, was recently approved by the US Food and Drug Administration for prophylactic use in patients with chronic stable angina. ISMN is the major active metabolite of isosorbide dinitrate (ISDN; Isordil, and others).
Med Lett Drugs Ther. 1992 Jun 26;34(873):61 |  Show IntroductionHide Introduction